Therefore, considering the poor prognosis associated with the elevated serum levels of bFGF in patients with prostate cancer, the use of combinational therapies could have a positive outcome for individuals resistant to traditional therapies [196]. The gene discussed is FGF2; the disease is prostate cancer.